191 related articles for article (PubMed ID: 12749507)
1. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers.
Martin PD; Dane AL; Schneck DW; Warwick MJ
Clin Ther; 2003 Feb; 25(2):459-71. PubMed ID: 12749507
[TBL] [Abstract][Full Text] [Related]
2. No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers.
Martin PD; Kemp J; Dane AL; Warwick MJ; Schneck DW
J Clin Pharmacol; 2002 Dec; 42(12):1352-7. PubMed ID: 12463730
[TBL] [Abstract][Full Text] [Related]
3. Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics.
Jones MR; Baker BA; Mathew P
Clin Pharmacokinet; 2004; 43(13):943-50. PubMed ID: 15509187
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers.
Martin PD; Warwick MJ; Dane AL; Cantarini MV
Clin Ther; 2003 Aug; 25(8):2215-24. PubMed ID: 14512129
[TBL] [Abstract][Full Text] [Related]
5. Effect of itraconazole on the pharmacokinetics of rosuvastatin.
Cooper KJ; Martin PD; Dane AL; Warwick MJ; Schneck DW; Cantarini MV
Clin Pharmacol Ther; 2003 Apr; 73(4):322-9. PubMed ID: 12709722
[TBL] [Abstract][Full Text] [Related]
6. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Ferdinand KC; Davidson MH; Kelly MT; Setze CM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
[TBL] [Abstract][Full Text] [Related]
7. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor.
Martin PD; Dane AL; Nwose OM; Schneck DW; Warwick MJ
J Clin Pharmacol; 2002 Oct; 42(10):1116-21. PubMed ID: 12362926
[TBL] [Abstract][Full Text] [Related]
8. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers.
Martin PD; Warwick MJ; Dane AL; Brindley C; Short T
Clin Ther; 2003 Oct; 25(10):2553-63. PubMed ID: 14667956
[TBL] [Abstract][Full Text] [Related]
9. Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.
Godfrey AR; Digiacinto J; Davis MW
Clin Ther; 2011 Jun; 33(6):766-75. PubMed ID: 21704241
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers.
Martin PD; Mitchell PD; Schneck DW
Br J Clin Pharmacol; 2002 Nov; 54(5):472-7. PubMed ID: 12445025
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study.
Li Y; Jiang X; Lan K; Zhang R; Li X; Jiang Q
Clin Ther; 2007 Oct; 29(10):2194-203. PubMed ID: 18042475
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study.
Roth EM; Rosenson RS; Carlson DM; Fukumoto SM; Setze CM; Blasetto JW; Khurmi NS; Stolzenbach JC; Williams LA
Cardiovasc Drugs Ther; 2010 Dec; 24(5-6):421-8. PubMed ID: 20953684
[TBL] [Abstract][Full Text] [Related]
13. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans.
Bergman AJ; Murphy G; Burke J; Zhao JJ; Valesky R; Liu L; Lasseter KC; He W; Prueksaritanont T; Qiu Y; Hartford A; Vega JM; Paolini JF
J Clin Pharmacol; 2004 Sep; 44(9):1054-62. PubMed ID: 15317833
[TBL] [Abstract][Full Text] [Related]
14. Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin.
Samineni D; Desai PB; Sallans L; Fichtenbaum CJ
J Clin Pharmacol; 2012 Jun; 52(6):922-31. PubMed ID: 21712498
[TBL] [Abstract][Full Text] [Related]
15. ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans.
Zhu T; Awni WM; Hosmane B; Kelly MT; Sleep DJ; Stolzenbach JC; Wan K; Chira TO; Pradhan RS
J Clin Pharmacol; 2009 Jan; 49(1):63-71. PubMed ID: 18952910
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
[TBL] [Abstract][Full Text] [Related]
17. Lack of an Effect of Ritonavir Alone and Lopinavir-Ritonavir on the Pharmacokinetics of Fenofibric Acid in Healthy Volunteers.
Gordon LA; Malati CY; Hadigan C; McLaughlin M; Alfaro RM; Calderón MM; Kovacs JA; Penzak SR
Pharmacotherapy; 2016 Jan; 36(1):49-56. PubMed ID: 26799348
[TBL] [Abstract][Full Text] [Related]
18. The effect of fluconazole on the pharmacokinetics of rosuvastatin.
Cooper KJ; Martin PD; Dane AL; Warwick MJ; Schneck DW; Cantarini MV
Eur J Clin Pharmacol; 2002 Nov; 58(8):527-31. PubMed ID: 12451430
[TBL] [Abstract][Full Text] [Related]
19. The effect of erythromycin on the pharmacokinetics of rosuvastatin.
Cooper KJ; Martin PD; Dane AL; Warwick MJ; Raza A; Schneck DW
Eur J Clin Pharmacol; 2003 May; 59(1):51-6. PubMed ID: 12682802
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]